



IFW 1644

APPLICANT: COLIN WATTS

EXAMINER:

PATENT
Client/Matter No. 350013-71
F. VANDERVEGT

SERIAL NO. 09/646,950

GROUP ART UNIT: 16544


FILED: DECEMBER 8, 2000

DOCKET NO. 350013-71

TITLE: USE OF INHIBITORS OF MAMMALIAN ASPARAGINYL ENDOPEPTIDE FOR
THERAPY OF AUTOIMMUNE DISEASE

Certificate of Mailing under 37 CFR 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service First Class and addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. BOX 1450, Alexandria, VA 22313-1450, on April 12, 2004


Elizabeth Bui

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop: Non-Fee Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

In response to Office Action of March 24, 2004, please enter the following response.

REMARKS:

Applicant thanks the Examiner for the Office Action of March 24, 2004, which has been studied with interest and care.

A substitute specification per 37 CFR 1.125(b) is enclosed. The specification, including the claims, has been amended to add sequence identifiers where at least 4 amino acids appear.

A paper copy of the substitute sequence listing per 37 CFR 1.821-1.825 is also enclosed.

A copy of the sequence listing in computer readable format (CRF) on a floppy disk per 37 CFR 1.821-1.825 is also enclosed.

The paper copy of the substitute sequence listing is *identical* to the CRF copy of the sequence listing found on the sequence listing.